← Back to patent-cliff list
Trofinetide
Tier C — Watch / tradeTrofinetide
Walter Reed Army Institute
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Neuropeptide receptor, Cytokines
Brand：Daybue
Indications (approved)：Rett syndrome
Regional status
US
Approved
2023-03-10
EU
Approved
2026-08-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Trofinetide?
Approved indications include: Rett syndrome.
When does the Trofinetide patent expire?
No public expiry year is available for Trofinetide yet; this page updates once verified.
How do I get a quote for Trofinetide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27